Advertising
Showing 1 to 15 of 23 entries

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 06/21, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has triggered its stop at $56. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 21% when combined with the previous recommendation to cover half the position.
biotechnology / pharmaceutical
DON'T BUY
They produced an early Covid vaccine, but got lost among other vaccines that were more effective. There are better fish to fry. They report Friday.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 06/21, Up 30%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has achieved its $64 objective. To remain disciplined, we recommend covering half the position here. We continue to recommend holding a stop loss at $56, which if triggered would result in a net investment return over 21% along with today's recommendation of covering half.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Apr 22/21, Up 22.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN is progressing well. We now recommend trailing the stop (from $42) to $56. If triggered, this would all but guarantee a net investment return of 13%.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly AZN is the COVID-19 vaccine producer that has been granted emergency use authorization in over 50 countries. It also has one of the best pipelines for new biotech drugs. They just acquired a strategic company that will further "boost" their immunology presence. The company pays a good dividend that is projected to have a payout ratio under 75% of cash flow next year. The company is estimated to have added over $2.3 billion to its cash reserves, which are now over $7.5 billion. We would buy this with a stop loss at $42, looking to achieve $64 -- upside potential of 28%. Yield 2.83% (Analysts’ price target is $63.73)
biotechnology / pharmaceutical
BUY on WEAKNESS
Allan Tong’s Discover Picks The AZN stock currently trades at a 64x PE and pays a not-bad 2.69% dividend yield. It's trending $7 below its $59.73 price target, and has declined slightly to June levels. However, its PE has tumbled to levels last seen in December 2019. Three analysts rate it a strong buy, one a buy and another a hold, unchanged since August. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
biotechnology / pharmaceutical
COMMENT

Their Covid vaccine in progress For most of the large-cap pharmas he owns, the benefits of producing this vaccine won't benefit these companies as much as people think. That said, AZN has been executing very well in areas like oncology--a key driver for them. In May, AZN's vaccine was his front runner in this race. AZN (with Oxford University) did have a negative reaction during their recent phase 3 test, though, so there is a risk here. However AZN has resumed tests outside the U.S., so expect results a little later. So now Pfizer has become the front runner. He's looking for the safety profile of AZN's candidate. If their vaccine is a miss, there will be stock volatility, but also a buying opportunity. A great company.

biotechnology / pharmaceutical

Unlock the Monthly Gems

Become a member Or, Sign In
TOP PICK
Paul McDonald also recommends GSK's peer, AstraZeneca (also trading in New York and London). The pharma is focusing on its pipeline of drugs that can't be easily replicated. A third of its sales comes from the U.S., plus 20% from China, which may actually be a tailwind in this context. The New York stock (AZN-N) pays a 2.87% dividend and the London one pays 2.95%
biotechnology / pharmaceutical
BUY

They have done what Pfizer is in the process of doing. They focused in on their pipeline with drugs that are difficult to replicate. Their immunotherapy drug has been doing well, and the chart looks great. The fundamentals of the business is good. Multiples are around 13x though one of the best EPS. He is generating good premiums on his positions.

biotechnology / pharmaceutical
HOLD
One of their perfect pharma holdings with well diversified and global holdings. It trades at a slight premium to the peer group, but that is warranted as it specializes in oncology. The company on has 33% of sales from the US which shelters itself somewhat from the politics of pharma. 20% of revenues come from China (where growth is 30% per year).
biotechnology / pharmaceutical
HOLD
AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.
biotechnology / pharmaceutical
HOLD
New oncology drugs. No problems owning it. If you're going to be in the pharma sector, buy one stock only. In the sector, half are up, and half are down. Yield is 3.3% and still growing, though not hugely.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Dec 11/17, Up 30%) They'd been struggling for years, but developed a bunch of new drugs. He thinks this will rise a lot higher.
biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick December 11/17 - Up 18%) The whole health care sector heated up over the last year. Very safe stock to hold. Nice dividend.

biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick May 10/17, Up 16%) It's a diversified biopharma out of the UK. Surprised many by annoucning phase 2 drug trial in lung cancer--a frontrunner in this space. Their main drivers is their immunotherapy business. A great growth profile in the industry, but need to execute on a few of these trials in the next 6-12 months. Own it with BMY-N and MRK-N and not alone.

biotechnology / pharmaceutical
Showing 1 to 15 of 23 entries

Astrazeneca P L C(AZN-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 4

Stockchase rating for Astrazeneca P L C is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Astrazeneca P L C(AZN-N) Frequently Asked Questions

What is Astrazeneca P L C stock symbol?

Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N

Is Astrazeneca P L C a buy or a sell?

In the last year, 4 stock analysts published opinions about AZN-N. 3 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Astrazeneca P L C.

Is Astrazeneca P L C a good investment or a top pick?

Astrazeneca P L C was recommended as a Top Pick by on . Read the latest stock experts ratings for Astrazeneca P L C.

Why is Astrazeneca P L C stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Astrazeneca P L C worth watching?

4 stock analysts on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.

What is Astrazeneca P L C stock price?

On 2022-01-28, Astrazeneca P L C (AZN-N) stock closed at a price of $59.31.